AVX 13616
Modify Date: 2024-01-09 11:00:58
AVX 13616 structure
|
Common Name | AVX 13616 | ||
|---|---|---|---|---|
| CAS Number | 900814-48-4 | Molecular Weight | 955.06 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C50H73Cl2N7O7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AVX 13616AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice. |
| Name | L-Leucine, N2-[2-[[(1S)-2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, hydrochloride (1:2) |
|---|---|
| Synonym | More Synonyms |
| Description | AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice. |
|---|---|
| Related Catalog | |
| References |
[1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences |
| Molecular Formula | C50H73Cl2N7O7 |
|---|---|
| Molecular Weight | 955.06 |
| PSA | 219.98000 |
| LogP | 10.81170 |
| Storage condition | 2-8℃ |
| L-Leucine, N2-[[[(1S)-2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, dihydrochloride |
| Leucine, N-[2-[[2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, hydrochloride (1:1) |
| 3-Methylbutyl N-({[2'-(3-methylbutoxy)-1,1'-binaphthalen-2-yl]oxy}acetyl)-D-lysyl-D-arginylleucinate hydrochloride (1:1) |
| AVX 13616 |